Guidant in vulnerable plaque pact with Miravant
This article was originally published in Clinica
Guidant and Miravant Medical Technologies are to collaborate on the development of a photodynamic therapy (PDT) for cardiovascular applications, including potential treatments for vulnerable plaque. As part of the agreement, Guidant will also make a staged equity investment in the company.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.